The UK Government has added to its list of industry-focused technical notices laying out its preparations for a possible no-deal Brexit.
National Health Service (NHS) England has announced it has come to a deal with Novartis to fund the use of its chimeric antigen receptor T-cell (CAR-T) immunotherapy Kymriah (tisagenlecleucel) for children and young adults under 25 years old with refractory acute lymphoblastic leukaemia (ALL).
The financial year of 2017/18 saw the highest number of organs ever donated in the UK.
A drone ambulance that is capable of operating autonomously while carrying a single injured passenger has been awarded $20,000 to fund its further development.
Concerns about the possibility of a no-deal Brexit in March 2019, when the UK begins its transitional period to leave the EU, have been expressed repeatedly by the pharmaceutical industry.
In recent months, one of US President Donald Trump’s focuses has been to reduce the price of medication in the US, all the way from the most expensive drugs to the cheapest.
Google, Amazon, and IBM joined forces with Microsoft, Salesforce, and Oracle to pledge to speed up the progress of health data standards and interoperability.
“The ability to continuously sense inside the human body has largely been a distant dream,” said Romit Roy Choudhury, professor of electrical engineering and computer science at the University of Illinois.
As the demand for new technologies in the medical field continues to grow, so too does the number of ambitious startups looking to fill gaps in the market and provide new solutions to persistent health issues.
There is no denying that artificial intelligence (AI) is becoming increasingly prevalent in almost every industry, including healthcare, with applications ranging from robot-assisted surgery to symptom-checking apps already on the market.
The new health secretary Matt Hancock has pledged a major funding package of £487m to transform technology in the NHS during a visit to West Suffolk Hospital.
The emerging field of gene editing has hit a significant roadblock as scientists have discovered CRISPR/Cas9, one of the newest and most promising tools for genome editing, can cause far more genetic damage than had previously been realised.
The US Food and Drug Administration (FDA) has outlined the need for advanced manufacturing techniques, such as 3D printed drugs, in the pharmaceutical industry.
Standing on the edge of a balcony, rescuing a cat from a tree, or performing tasks on the tenth storey of a building.
US President Donald Trump is “likely” to pressure the UK to change its pharmaceutical regulations as part of post-Brexit trade negotiations, according to an op-ed published in leading medical journal The Lancet.
Researchers believe they have found a way to turn the neural circuits in the brain on and off without using surgery.
Yesterday the UK’s National Health Service celebrated its 70th birthday.
Engineers from Tufts University have developed a prototype smart bandage that can actively monitor chronic wounds and automatically deliver drug treatments to improve the chances of healing.
Scientists at the University of Glasgow are developing a synthetic e-skin that can mimic the sense of touch on a robotic hand.
Last week, the US Food and Drug Administration (FDA) approved Epidiolex for the treatment of seizures associated with two rare and severe forms of epilepsy.
Blockchain is the digital ledger technology that is sweeping through a number of industries on a wave of hype.
The UK’s National Health Service (NHS) has been urged to embrace full automation, including bedside robots and AI diagnoses, to free up frontline staff time worth up to £12.5bn a year – almost 10% of its annual running cost.
Surgery, radiation therapy and chemotherapy have long been the go-to for cancer treatment.
The early and accurate diagnosis of autism spectrum disorder (ASD) in children is crucial.
In the US, organs are in such high demand that 20 people die every day waiting for a transplant.
Japan’s Takeda Pharmaceutical this week agreed to buy Ireland’s Shire for $65 billion.
Japan’s Takeda has agreed to buy Dublin-based Shire Pharmaceuticals for £46 billion ($64.42 billion), in what is the sector’s biggest deal since 2000.
Swiss pharmaceuticals giant Novartis is buying US gene therapy pioneers AveXis for $8.7 billion, in a bid to boost its leadership in neuroscience treatment.
Scientists have predicted that the next flu pandemic to hit the UK could kill as many as 886,000 people and infect 43 million — about three-quarters of the entire population.
A major study into haemotopoietic stem cell transplantation treatment for Multiple Sclerosis has found that it is “stunningly” better than drug treatments, according to one of the doctors involved.